These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 85322)

  • 1. Chemoimmunotherapy versus chemotherapy for remission induction in patients with non-Hodgkin's lymphoma: progress report of a Southwest Oncology Group study.
    Jones SE
    Recent Results Cancer Res; 1978; 65():164-9. PubMed ID: 85322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study.
    Jones SE; Grozea PN; Metz EN; Haut A; Stephens RL; Morrison FS; Butler JJ; Byrne GE; Moon TE; Fisher R; Haskins CL; Coltman CA
    Cancer; 1979 Feb; 43(2):417-25. PubMed ID: 84706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study.
    Jones SE; Grozea PN; Metz EN; Haut A; Stephens RL; Morrison FS; Talley R; Butler JJ; Byrne GE; Hartsock R; Dixon D; Salmon SE
    Cancer; 1983 Mar; 51(6):1083-90. PubMed ID: 6185212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study.
    Grozea PN; Jones SE; McKelvey EM; Coltman CA; Fisher R; Haskins CL
    Cancer Treat Rep; 1979 Apr; 63(4):647-53. PubMed ID: 87277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of BCG on peripheral blood counts and drug tolerance of patients with non-Hodgkin lymphoma receiving combination chemotherapy.
    Brooks RJ; Jones SE; Gaines JA
    Med Pediatr Oncol; 1978; 5(1):1-7. PubMed ID: 85250
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study.
    Jones SE; Grozea PN; Miller TP; Van Slyck EJ; Balcerzak SP; Costanzi JJ; Morrison FS; Eyre HJ; Fabian CJ; Dabich L
    J Clin Oncol; 1985 Oct; 3(10):1318-24. PubMed ID: 3900301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation.
    Weick JK; Antunez A; Kraus TA; Fabian CJ; Dixon D
    Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1205-7. PubMed ID: 6347997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphoma.
    Johnson GJ; Costello WG; Oken MM; Sponzo RW; Barnes JM; Ezdinli EZ; Bennett JM; Silverstein MN; Glick JH; Berard CW
    Cancer; 1983 Oct; 52(7):1133-41. PubMed ID: 6192894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
    O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
    J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
    Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
    Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A comparative study of CHOP therapy and COP-BLAM therapy for non-Hodgkin's lymphoma in elderly patients].
    Arai N; Hara A; Kaneko H; Umeda M; Shirai T
    Nihon Ronen Igakkai Zasshi; 1991 Sep; 28(5):672-7. PubMed ID: 1721658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
    Sampi K; Honda T; Hattori M; Takayama S
    Gan To Kagaku Ryoho; 1983 May; 10(5):1266-71. PubMed ID: 6191677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.